Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Arthritis and Rheumatism|August 12, 2003
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort studyAngelo Ravelli, Carolina Duarte-Salazar, Silvia Buratti, et al.
Modern Rheumatology|July 29, 2015
A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in JapanRyoki Hara, Hirotaka Miyazawa, Kenichi Nishimura, et al.
Modern Rheumatology|July 5, 2023
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillanceMasataka Kuwana, Naonobu Sugiyama, Shigeki Momohara, et al.
Arthritis and Rheumatism|June 10, 2004
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damageNicolino Ruperto, Silvia Buratti, Carolina Duarte-Salazar, et al.
Clinical Rheumatology|October 12, 2012
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in JapanTomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi, et al.
RMD Open|September 17, 2021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparisonHermine I Brunner, Carlos Abud-Mendoza, Masaaki Mori, et al.
Modern Rheumatology|September 5, 2019
Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) in Japan: Multi-center retrospective descriptive studySayaka Tsuda, Azusa Sameshima, Michikazu Sekine, et al.
Modern Rheumatology|March 7, 2025
Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: final analysis of an all-case post-marketing surveillance studyMasataka Kuwana, Naonobu Sugiyama, Shigeki Momohara, et al.
Rheumatology (Oxford, England)|January 18, 2020
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT studyYoshikazu Nakaoka, Mitsuaki Isobe, Yoshiya Tanaka, et al.
The Journal of Allergy and Clinical Immunology|February 2, 2021
Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivationHiroshi Nihira, Kazushi Izawa, Moeko Ito, et al.
Pageof 9